Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Next Previous
X
Search
Trial Profile

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Belvarafenib (Primary) ; Camonsertib (Primary) ; Divarasib (Primary) ; Entrectinib (Primary) ; Idasanutlin (Primary) ; Inavolisib (Primary) ; Ipatasertib (Primary) ; Pralsetinib (Primary) ; Trastuzumab emtansine (Primary)
  • Indications Adrenal cancer; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastrointestinal cancer; Gynaecological cancer; Head and neck cancer; Neuroblastoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Pancreatic cancer; Penile cancer; Prostate cancer; Salivary gland cancer; Sarcoma; Solid tumours; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms TAPISTRY
  • Sponsors Roche

    • Most Recent Events

    • 04 Jun 2024 Results (At data cut-off: 9 Nov 2023; n=150) assessing efficacy and safety data of atezolizumab in adult and pediatric pts with TMB-high advanced/metastatic solid tumors from Cohort D, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2024 Results (at data cut-off 16 Jul 2023, n=50) assessing efficacy and safety data of Cohort E, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 25 Jan 2024 According to a Repare Therapeutics media release, under its worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib, it has earned a $40 million milestone payment from Roche upon dosing of the first patient with camonsertib (RP-3500 or RG6526) in Roche's TAPISTRY trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top